Zip, I don't think Tats is entirely wrong about GLP-1 drugs. However...If Vascepa DOES prove to have legit efficacy against AD (even if it's not considered as "effective" as GLP-1 drugs), if Amarin (or BP) does a good enough job of PR/marketing its effectiveness, people and docs will be ALL OVER it because if its safety profile (and cost vs. GLP-1's). AND...rather than NEGATIVE side-effects, you are talking about POSITIVE side-effects from taking Vascepa. Shit, it's just a more efficient delivery system for EPA. So if docs and pts could all understand the net positive outcomes of taking Vascepa, it could be HUGE.